Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty
Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty
This is a prospective, multicentric, comparative, non-randomized interventional study in
 which subjects diagnosed with central precocious puberty (CPP) and early puberty (EP) were
 treated for 6 months to compare the effect with GnRHa and traditional Chinese medicines.
740 girls with CPP and EP participated in this study, all participates were divided into
 GnRHa group, traditional chinese medicines group and blank group. After at least six months
 therapy with GnRHa or traditional Chinese medicines, the investigators compare clinical
 parameters, sex hormone, bone age and ovarian ultrasound in three groups.
Inclusion Criteria:

 1. Premature appearance of secondary sexual characteristics: girls present with
 development of secondary sexual characteristics before 8, with breast induration as
 the earliest manifestation.

 2. Accelerated linear growth: the annual growth rate is higher than normal.

 3. Advanced bone age: the bone age is 1 or years more than the actual age

 4. Enlargement of sexual glands: B-mode ultrasonography of pelvic cavity indicates the
 volumes of the uterus and ovaries have increased, and multiple ovarian follicles with
 a diameter>4mm can be found in ovaries;

 5. HPGA functions have been primed; serum gonadotropin and sexual hormone levels reach
 pubertal values.

 6. Subjects should be willing and able to follow the study protocol during the study
 period.

 7. Subjects should submit their parents' or guardians' written informed consent before
 initiation of the study procedure with non-normal medical care. They should understand
 that subjects or their parents/guardians may withdraw the consent at any time without
 impairing future medical care. If the child is old enough to read and write, she
 should submit a separate consent form.

 Exclusion Criteria:

 1. Patients with central nervous system diseases and thyroid diseases;

 2. Patients with CHA-induced precocious puberty;

 3. Patients with poor compliance.